


Is there a role for radiotherapy and chemoradiotherapy in pancreatic cancer ?

Locally-Advanced PC

Christophe LOUVET, MD, PhD
Hôpital St-Antoine
Université Paris VI
Paris, France

Barcelona, June 24th



Locally Advanced Disease in Pancreatic Cancer Trials

Trial	Treatment arms	n	% Loc Adv	Survival	
				LA	Met
Berlin	Gem +/- 5FU	322	10%	7.5	5.8
Louvet	Gem +/- Oxaliplatin	313	31%	10.3	8.5
Moore	Gem +/- Erlotinib	569	24%	9.0	5.9
Herrmann	Gem +/- Cape	319	20%		RR 1.48
Cunningham	Gem +/- Cape	533	29%	9.9	6.1

Role of RT or CRT in LAPC ?

Chemoradiotherapy in the Management of Locally-Advanced Pancreatic Carcinoma: A Qualitative Systematic Review

Florence HUGUET and coll

JCO 2009, May 1, vol 27, 13 :2269-77

Role of RT or CRT in LAPC ? : Summary

RTCT > BSC

RTCT > RT

Role of RT or CRT in LAPC ? : Summary

RTCT > BSC


RTCT > RT

RTCT non different as compared to CT, higher toxicity

First-intention CRT : FFCD-SFRO trial

Chauffert et al, Ann Oncol 2008, 19(9): 1592-99

119 patients included



**CHRT : 60 Gy, 2 Gy/fraction,
 5FU 300 mg/m²/d d1-5 x 6w
 cisplatin 20 mg/m²/d d1-5 w 1 and 5**

Gemcitabine : 1000 mg/m² weekly, 3w/4w

Median survival : CHRT = 8.6 months vs gemcitabine = 13 months (p =.03)

1-year survival : CRT = 32 % vs gemcitabine = 53 %

Role of RT or CRT in LAPC ? : Summary



RTCT > BSC

RTCT > RT

RTCT non different as compared to CT, higher toxicity

No nodal RT probably equivalent and less toxic as compared to conventional RT

RT modalities

Conventional

No Nodal RT

No phase III trial, but « no nodal » RT seems to decrease toxicity without efficacy impairment

Role of RT or CRT in LAPC ? : Summary

RTCT > BSC

RTCT > RT

RTCT non different as compared to CT, higher toxicity

No nodal RT probably equivalent and less toxic as compared to conventional RT

RT combined to 5FU remains the reference, gem should be tested in phase III

CRT modalities

		OS (med)	p
GITSG, 1985 N = 30 pts	RT 60 Gy + 5FU	8.5 m	NS tox +++
	RT 40 Gy + Doxo, then Doxo + 5FU	7.6 m	
EARLE, 1994 N = 87 pts	RT 55 Gy + 5FU	7.8 m	NS tox +++
	RT 50 Gy + hycanthone	7.8 m	
CRANE, 2002 N = 114 pts (retrosp)	RT 30 Gy + 5FU (n = 61)	9.0 m	NS
	RT 30 Gy + Gem (n = 53)	11.0 m	
LI, 2003 N = 34 pts	RT 50.4 – 61.2 Gy + 5FU, then Gem	6.7 m	0.02
	RT 50.4 – 61.2 Gy + Gem, then Gem	14.5 m	
CHUNG, 2004 N = 48 pts	RT 45 Gy + Gem + doxifluridine	12.0 m	NS
	RT 45 Gy + paclitaxel + doxifluridine	14.0 m	
WILKOWSKI, 2006 N = 96 pts	RT 50 Gy + 5FU	9.6 m	NS
	RT 50 Gy + Gem + Cispl	9.6 m	
	RT 50 Gy + Gem + Cispl, then Gem + Cispl	6.1 m	

5FU remains the reference. Gem should be tested in phase III

Role of RT or CRT in LAPC ? : Summary

RTCT > BSC


RTCT > RT

RTCT non different as compared to CT, higher toxicity

No nodal RT probably equivalent and less toxic as compared to conventional RT

RT combined to 5FU remains the reference, gem should be tested in phase III

Quality assurance mantated





How to manage CT and CRT in LAPC ?

Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies
Florence Hagot, Thierry André, Pascal Hamon, Pascal Artru, Jacques Delvaux, Frédéric Sella, Elizabeth Dumont-Alexandre, Philippe Razousov, Emmanuel Touboul, Roberto Labianca, Anthony de Craenen, and Christophe Louvet

VOLUME 25 : NUMBER 3 : JANUARY 26 2007

JOURNAL OF CLINICAL ONCOLOGY



Induction ChT + EBRT: MD Anderson experience (KRISHNAN, Cancer 2007)

323 Pts with Locally Advanced Pancreatic Cancer (1993-2005):

- 247 Pts: CRT (5-FU, Cap, Gem)
- 76 Pts: CT (Gem/CDDP), then CRT

MD Anderson Results



	#Pts	Median Overall Survival (months)	Median Time to LP (months)	Median Time to DP (months)
Induction CT, then CRT	76	11.9	8.9	9.5
CRT	247	8.5	6.0	5.6

Conclusion

Chemotherapy before CRT can identify pts who might potentially benefit from CRT and avoids CRT for patients with rapid progression of the disease

After control of disease by induction CT, CRT could significantly improve survival in LA pancreatic cancer compared to CT alone

A **prospective** validation is mantated



LAP07 study

As of June 22th, 2009	120 patients included
	118 in France (opened : 2/08)
	2 in Belgium (opened : 5/09)
No US participation	
Expected participation	Australia Canada (NCI-C) Spain (TTD) Germany (AIO) Sweden Italy (Giscad)